skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Fragment Optimization of Reversible Binding to the Switch II Pocket on KRAS Leads to a Potent, In Vi

Journal Article · · J. Med. Chem.

Research Organization:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
DOE - Office Of Science; National Institutes of Health (NIH)
OSTI ID:
1902372
Journal Information:
J. Med. Chem., Vol. 65, Issue (21)
Country of Publication:
United States
Language:
ENGLISH

References (26)

Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants journal January 2022
RAS Proteins and Their Regulators in Human Disease journal June 2017
Human RAS Superfamily Proteins and Related GTPases journal September 2004
A Ras-induced conformational switch in the Ras activator Son of sevenless journal October 2006
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? journal November 2010
RAS-targeted therapies: is the undruggable drugged? journal June 2020
The structural basis of the activation of Ras by Sos journal July 1998
Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism journal January 2016
A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand journal August 2014
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity journal March 2012
Discovery of Small Molecules that Bind to K-Ras and Inhibit Sos-Mediated Activation journal May 2012
Drugging all RAS isoforms with one pocket journal November 2020
Drugging an undruggable pocket on KRAS journal July 2019
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions journal November 2013
The path to the clinic: a comprehensive review on direct KRASG12C inhibitors journal January 2022
Identification of the Clinical Development Candidate MRTX849 , a Covalent KRAS G12C Inhibitor for the Treatment of Cancer journal April 2020
Discovery of a Covalent Inhibitor of KRAS G12C (AMG 510) for the Treatment of Solid Tumors journal December 2019
Using chemical shift perturbation to characterise ligand binding journal August 2013
Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors journal January 2022
High-Throughput Kinetic Characterization of Irreversible Covalent Inhibitors of KRASG12C by Intact Protein MS and Targeted MRM journal January 2022
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity journal October 2019
Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity journal November 2017
Intrinsic reactivity profile of electrophilic moieties to guide covalent drug design: N-α-acetyl-l-lysine as an amine nucleophile journal January 2016
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor journal December 2021
Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity journal January 2019
Abstract 1271: In vitro and in vivo characterization of BI 1823911 - a novel KRASG12C selective small molecule inhibitor journal July 2021